Jiantao Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jiantao Liu has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Chengbo Liu
Research Center for Biomedical Optics and Molecular Imaging, Key Laboratory of Biomedical Imaging Science and System, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China
1 shared publication - Chenshuang Zhang
Shenzhen University 8
1 shared publication - Feng Shen
Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China
1 shared publication - Hao Xu
Center for Biomedical Optics and Photonics, College of Physics and Optoelectronic Engineering, Shenzhen University, Shenzhen, People’s Republic of China
1 shared publication - Iuliia Golovynska
Center for Biomedical Optics and Photonics, College of Physics and Optoelectronic Engineering, Shenzhen University, Shenzhen, People’s Republic of China
1 shared publication - Junle Qu
Shenzhen University
1 shared publication
Latest Publications
- 8 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
ANXA1 Promotes Endoplasmic Reticulum–Mitochondria Calcium Coupling to Sustain Lenvatinib Resistance in Hepatocellular Carcinoma
Lenvatinib is the most widely used first-line treatment for advanced hepatocellular carcinoma (HCC). Nevertheless, drug resistance remains a major clinical challenge, highlighting the need to identify the underlying mechanistic drivers. Here, we identified a role for annexin A1 (ANXA1) in promoting lenvatinib resistance by supporting endoplasmic reticulum (ER)–mitochondria communication. Live-cell structured illumination microscopy revealed that ANXA1 deficiency induced the dissociation of ER–mitochondria contact sites (ERMCS), and Ca2+ kinetic analysis revealed that ANXA1 enhanced mitochondrial Ca2+ coupling. ANXA1 promoted ERMCS by directly binding the ER–mitochondria Ca2+ transfer tethers GRP75 and ITPR1 and promoting their interaction. Functionally, ANXA1 sustained oxidative phosphorylation following lenvatinib treatment and promoted cell survival. We further found that ANXA1 RNA stability was governed by an 8-oxoguanine modification–mediated ROS feedback loop. Therapeutically, photoacoustic imaging–guided in vivo analyses demonstrated that targeting this epigenetic–organelle communication feedback loop resensitized HCC to lenvatinib treatment, inhibiting peritumoral angiogenesis and improving the intratumoral hypoxic microenvironment. These findings uncover ERMCS formation as a driver of lenvatinib resistance in HCC, establishing a potential therapeutic strategy for targeting organelle communication to reverse drug resistance.
- 8 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
ANXA1 Promotes Endoplasmic Reticulum–Mitochondria Calcium Coupling to Sustain Lenvatinib Resistance in Hepatocellular Carcinoma
Lenvatinib is the most widely used first-line treatment for advanced hepatocellular carcinoma (HCC). Nevertheless, drug resistance remains a major clinical challenge, highlighting the need to identify the underlying mechanistic drivers. Here, we identified a role for annexin A1 (ANXA1) in promoting lenvatinib resistance by supporting endoplasmic reticulum (ER)–mitochondria communication. Live-cell structured illumination microscopy revealed that ANXA1 deficiency induced the dissociation of ER–mitochondria contact sites (ERMCS), and Ca2+ kinetic analysis revealed that ANXA1 enhanced mitochondrial Ca2+ coupling. ANXA1 promoted ERMCS by directly binding the ER–mitochondria Ca2+ transfer tethers GRP75 and ITPR1 and promoting their interaction. Functionally, ANXA1 sustained oxidative phosphorylation following lenvatinib treatment and promoted cell survival. We further found that ANXA1 RNA stability was governed by an 8-oxoguanine modification–mediated ROS feedback loop. Therapeutically, photoacoustic imaging–guided in vivo analyses demonstrated that targeting this epigenetic–organelle communication feedback loop resensitized HCC to lenvatinib treatment, inhibiting peritumoral angiogenesis and improving the intratumoral hypoxic microenvironment. These findings uncover ERMCS formation as a driver of lenvatinib resistance in HCC, establishing a potential therapeutic strategy for targeting organelle communication to reverse drug resistance.
- Open Access
- 7 December 2025
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 17 (1)
Human stem cells loaded with visible and near-infrared fluorescent core–shell polymeric nanoparticles and revealing tropism toward inflammatory stimuli: in vitro evaluation
Theranostic approach based on fluorescent nanoparticles (NPs) internalized by stem cells (SCs) injected in the bloodstream allows for reaching cancer or in
- 7 December 2025
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 17 (1)
Open AccessHuman stem cells loaded with visible and near-infrared fluorescent core–shell polymeric nanoparticles and revealing tropism toward inflammatory stimuli: in vitro evaluation
Theranostic approach based on fluorescent nanoparticles (NPs) internalized by stem cells (SCs) injected in the bloodstream allows for reaching cancer or in